PD-Rx Pharmaceuticals, Inc. is recalling various bottle sizes of ranitidine hydrochloride USP, 150 mg tablets due to potential contamination with N-nitrosodimethylamine (NDMA) at levels higher than allowed by the FDA. Ranitidine is a prescription medication commonly used to treat and prevent ulcers in the stomach and intestines, as well as gastroesophageal reflux disease (GERD). This recall was initiated after the supplier notified the company that the drug may contain this impurity, which is classified as a probable human carcinogen. Consumers who have these tablets should contact their healthcare provider or pharmacist to discuss alternative treatments.
The product may contain N-nitrosodimethylamine (NDMA), a substance classified as a probable human carcinogen that can cause cancer with long-term exposure. While no immediate injuries have been reported, the levels of NDMA detected may exceed safety limits established by health authorities.
Full refund upon return of product.
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.